Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos

N0289

Sigma-Aldrich

Nafamostat mesylate

≥98% (HPLC), powder, serine protease inhibitor

Sinónimos:

4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate, FUT-175

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C19H17N5O2 · 2CH4O3S
Número de CAS:
82956-11-4
Peso molecular:
539.58
MDL number:
MFCD00941430
UNSPSC Code:
51111800
PubChem Substance ID:
329818423
NACRES:
NA.77

product name

Nafamostat mesylate, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear
H2O: >10 mg/mL

storage temp.

room temp

SMILES string

CS(O)(=O)=O.CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc3cc(ccc3c2)C(N)=N

InChI

1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)

InChI key

SRXKIZXIRHMPFW-UHFFFAOYSA-N

Application

Nafamostat mesylate has been used:
  • as a serine protease inhibitor to study its effects on proteolytic degradation of therapeutic proteins recombinantly expressed in Chinese hamster ovary (CHO)-K1-derived cells
  • to stop complement activation to validate the assay for murine C3 fragments
  • as a serine protease inhibitor to study its effects on house dust mite extract evoked Ca2+ entry

Biochem/physiol Actions

Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.
Nafamostat mesylate is used in the treatment of disseminated intravascular coagulation (DIC), pancreatitis, and systemic inflammatory response syndrome. It can block the proliferation, adhesion, and invasion of cancer cells and repress tumor progression in animal models. Nafamostat mesylate is involved in the development of immune activity. In combination with favipiravir, nafamostat mesylate may block virus entry and replication, and inhibit the pathogenic host response. This combination treatment might be effective for critically ill Covid-19 patients.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361fd

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Catherine Martel et al.
PloS one, 6(4), e18812-e18812 (2011-04-29)
The activation of complement during platelet activation is incompletely understood. We sought to explore the formation of C5b-9 and anaphylatoxins binding to collagen-activated platelets. C5b-9, anaphylatoxins C3a, C4a and C5a, and anaphylatoxin receptors C3aR1 and C5aR were measured by flow
Yu-Ping Lin et al.
Molecular cell, 70(2), 228-241 (2018-04-21)
The house dust mite is the principal source of perennial aeroallergens in man. How these allergens activate innate and adaptive immunity is unclear, and therefore, there are no therapies targeting mite allergens. Here, we show that house dust mite extract
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Markus Hoffmann et al.
Antimicrobial agents and chemotherapy, 64(6) (2020-04-22)
Claire Rolland-Fourcade et al.
Gut, 66(10), 1767-1778 (2017-01-18)
Proteases are key mediators of pain and altered enteric neuronal signalling, although the types and sources of these important intestinal mediators are unknown. We hypothesised that intestinal epithelium is a major source of trypsin-like activity in patients with IBS and
Xi Chen et al.
Frontiers in oncology, 9, 852-852 (2019-09-26)
Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of
Ver todos los artículos relacionados

Artículos

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico